4ZG Stock Overview
Develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Median Technologies SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.71 |
| 52 Week High | €7.31 |
| 52 Week Low | €2.09 |
| Beta | 1.48 |
| 11 Month Change | -9.41% |
| 3 Month Change | -48.97% |
| 1 Year Change | -11.68% |
| 33 Year Change | -76.90% |
| 5 Year Change | n/a |
| Change since IPO | -48.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4ZG | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -11.8% | -0.6% | -1.3% |
| 1Y | -11.7% | -33.0% | 7.4% |
Return vs Industry: 4ZG exceeded the German Healthcare Services industry which returned -33.1% over the past year.
Return vs Market: 4ZG underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 4ZG volatility | |
|---|---|
| 4ZG Average Weekly Movement | 11.9% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4ZG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4ZG's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 250 | Fredrik Brag | www.mediantechnologies.com |
Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device for early diagnosis of cancers and fibrotic diseases; iSee for image analysis services in clinical trials; and iCRO, which engages in the sale of imaging services for clinical trials in oncology using software. The company was founded in 2002 and is based in Valbonne, France.
Median Technologies SA Fundamentals Summary
| 4ZG fundamental statistics | |
|---|---|
| Market cap | €63.01m |
| Earnings (TTM) | -€25.35m |
| Revenue (TTM) | €22.32m |
2.8x
P/S Ratio-2.5x
P/E RatioIs 4ZG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4ZG income statement (TTM) | |
|---|---|
| Revenue | €22.32m |
| Cost of Revenue | €24.67m |
| Gross Profit | -€2.34m |
| Other Expenses | €23.01m |
| Earnings | -€25.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | -10.51% |
| Net Profit Margin | -113.57% |
| Debt/Equity Ratio | -138.8% |
How did 4ZG perform over the long term?
See historical performance and comparison